福斯達(603173.SH):2022年簽訂合同訂單約37.75億元
格隆匯4月28日丨有投資者向福斯達(603173.SH)提問:我瞭解到深冷技術賽道前景廣闊,近年來市場需求日益擴大。依託這樣的行業大背景,請問公司2022年的訂單進展及來源情況如何?請簡要介紹下。
福斯達回覆:2022年全年簽訂合同訂單約37.75億元。其中籤訂了1套福斯達目前最大等級的日處理量200萬Nm3天然氣液化裝置,海外簽訂了特大型制氮機組,總制氮量達22萬Nm3/h等。從簽訂項目數量、訂單金額以及完成年初公司制訂目標百分比來看,國內國外都超額完成既定目標。從訂單來源來看,國內外訂單量超半數均來源於既有老客户,公司形成了一批鐵粉客户,能持續帶來訂單和銷售業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.